Quviviq, a medication for treating insomnia, generated $107.6 million in net sales during 2023 [1]. In the fourth quarter of 2023, sales reached $34.8 million [1].
How is Quviviq performing compared to expectations?
In 2023, Quviviq achieved 82% of its projected sales target [1]. The company anticipates stronger sales in 2024, projecting between $200 million and $250 million [1].
What is Quviviq used for?
Quviviq is a prescription medication approved to treat adults with insomnia, characterized by difficulty with sleep onset or sleep maintenance [2].
How does Quviviq work?
Quviviq is a dual-orexin receptor antagonist [2]. Orexin is a neurotransmitter that promotes wakefulness, and by blocking its action, Quviviq helps to reduce the drive for wakefulness and facilitate sleep [2].
When did Quviviq receive approval?
The U.S. Food and Drug Administration (FDA) approved Quviviq in January 2022 [2].
What are the potential side effects of Quviviq?
Common side effects associated with Quviviq include somnolence, headache, dizziness, and nausea [2]. It carries a risk of serious side effects such as worsening or new-onset depression, suicidal thoughts or behaviors, and sleep paralysis [2].
What is the patent status for Quviviq?
Information regarding specific patent expirations for Quviviq is available through DrugPatentWatch.com [3]. DrugPatentWatch.com tracks patents and exclusivity for pharmaceutical products, which can indicate when generic competition might be possible [3].
Who manufactures Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [2].
What are the different dosages of Quviviq?
Quviviq is available in two dosage strengths: 25 mg and 50 mg [2].
What should patients consider before taking Quviviq?
Patients should inform their healthcare provider about any pre-existing mental health conditions, including depression or suicidal thoughts, as Quviviq may worsen these conditions [2]. It is also important to discuss other medications being taken to avoid potential interactions [2]. Driving or operating machinery should be avoided if somnolence persists [2].
---
Sources:
[1] https://www.businesswire.com/news/home/20240207015698/en/Idorsia-Announces-2023-Full-Year-Results-and-Provides-2024-Guidance-and-Outlook-for-2025
[2] https://www.quviviq.com/
[3] https://drugpatentwatch.com/